CG Oncology (NASDAQ:CGON) Director Leonard Post Sells 1,000 Shares

CG Oncology, Inc. (NASDAQ:CGON) Director Leonard Post sold 1,000 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $54.50, for a total value of $54,500.00. Following the completion of the sale, the director owned 1,000 shares in the company, valued at approximately $54,500. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

CG Oncology Trading Down 4.2%

CGON stock opened at $53.72 on Friday. CG Oncology, Inc. has a 1-year low of $23.65 and a 1-year high of $75.50. The firm has a market cap of $4.74 billion, a P/E ratio of -23.06 and a beta of 0.31. The business’s 50 day moving average is $65.98 and its 200-day moving average is $56.03.

CG Oncology (NASDAQ:CGON) last released its quarterly earnings data on Friday, May 8th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.13). The firm had revenue of $1.08 million during the quarter, compared to the consensus estimate of $0.45 million. Sell-side analysts forecast that CG Oncology, Inc. will post -2.89 EPS for the current year.

Wall Street Analysts Forecast Growth

CGON has been the topic of a number of research analyst reports. Truist Financial restated a “buy” rating and set a $82.00 price target (up from $77.00) on shares of CG Oncology in a research report on Thursday, May 14th. JPMorgan Chase & Co. upped their price objective on CG Oncology from $91.00 to $96.00 and gave the stock an “overweight” rating in a report on Monday, May 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CG Oncology in a report on Monday, April 20th. Wolfe Research initiated coverage on CG Oncology in a report on Tuesday, May 19th. They set a “peer perform” rating on the stock. Finally, Royal Bank Of Canada upped their price objective on CG Oncology from $79.00 to $81.00 and gave the stock an “outperform” rating in a report on Monday, May 11th. Eleven analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $81.73.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in CGON. Wellington Management Group LLP lifted its stake in shares of CG Oncology by 190.3% in the 3rd quarter. Wellington Management Group LLP now owns 5,512,779 shares of the company’s stock valued at $222,055,000 after purchasing an additional 3,613,885 shares during the period. Price T Rowe Associates Inc. MD lifted its stake in shares of CG Oncology by 116.7% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,443,144 shares of the company’s stock valued at $142,961,000 after purchasing an additional 1,854,386 shares during the period. Seven Fleet Capital Management LP acquired a new position in shares of CG Oncology in the 4th quarter valued at $62,909,000. Bank of America Corp DE lifted its stake in shares of CG Oncology by 409.9% in the 2nd quarter. Bank of America Corp DE now owns 1,736,769 shares of the company’s stock valued at $45,156,000 after purchasing an additional 1,396,170 shares during the period. Finally, State Street Corp lifted its stake in shares of CG Oncology by 46.4% in the 4th quarter. State Street Corp now owns 2,996,695 shares of the company’s stock valued at $124,423,000 after purchasing an additional 950,028 shares during the period. Institutional investors and hedge funds own 26.56% of the company’s stock.

CG Oncology Company Profile

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.